TolerogenixX Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

TolerogenixX General Information

Description

Developer of a patented and clinically tested cell therapy technique created for individualized immunosuppression in transplant patients. The company's cell therapy technique helps in the targeted disabling of undesired reactions caused by the immune system's defenses, enabling patients who received transplants to become tolerant of the donated organ.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Im Neuenheimer Feld 162
  • 69120 Heidelberg
  • Germany
+49 0162
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Im Neuenheimer Feld 162
  • 69120 Heidelberg
  • Germany
+49 0162

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TolerogenixX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private Completed Generating Revenue
5. Later Stage VC (Series A) 06-Jul-2023 Completed Generating Revenue
4. Later Stage VC 22-Nov-2019 Completed Generating Revenue
3. Early Stage VC Cancelled Generating Revenue
2. Seed Round 01-Jun-2017 Completed Generating Revenue
1. Grant 14-Jul-2015 $27.9K Completed Clinical Trials - Phase 2
To view TolerogenixX’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TolerogenixX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a patented and clinically tested cell therapy technique created for individualized immunosuppression in tra
Drug Discovery
Heidelberg, Germany
4 As of 2026

London, United Kingdom
 

Martinsried, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TolerogenixX Competitors (3)

One of TolerogenixX’s 3 competitors is Maxion Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Maxion Therapeutics Venture Capital-Backed London, United Kingdom
SciRhom Venture Capital-Backed Martinsried, Germany
Quell Therapeutics Venture Capital-Backed London, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

TolerogenixX Patents

TolerogenixX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019447492-A1 Mic therapy for specific immunosuppression in transplantation Active 17-May-2019
AU-2019447492-B2 Mic therapy for specific immunosuppression in transplantation Active 17-May-2019
CA-3139853-A1 Mic therapy for specific immunosuppression in transplantation Pending 17-May-2019
EP-3784253-A1 Mic therapy for specific immunosuppression in transplantation Active 17-May-2019
EP-3784253-B1 Mic therapy for specific immunosuppression in transplantation Active 17-May-2019 A61P37/06
To view TolerogenixX’s complete patent history, request access »

TolerogenixX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TolerogenixX Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kalodion Family Office Minority
Bundesministerium für Wirtschaft und Klimaschutz Government Minority
High-Tech Gründerfonds Venture Capital Minority
Science4Life Accelerator/Incubator
To view TolerogenixX’s complete investors history, request access »

TolerogenixX FAQs

  • When was TolerogenixX founded?

    TolerogenixX was founded in 2006.

  • Where is TolerogenixX headquartered?

    TolerogenixX is headquartered in Heidelberg, Germany.

  • What is the size of TolerogenixX?

    TolerogenixX has 4 total employees.

  • What industry is TolerogenixX in?

    TolerogenixX’s primary industry is Drug Discovery.

  • Is TolerogenixX a private or public company?

    TolerogenixX is a Private company.

  • What is TolerogenixX’s current revenue?

    The current revenue for TolerogenixX is .

  • How much funding has TolerogenixX raised over time?

    TolerogenixX has raised $12.6M.

  • Who are TolerogenixX’s investors?

    Kalodion, Bundesministerium für Wirtschaft und Klimaschutz, High-Tech Gründerfonds, and Science4Life have invested in TolerogenixX.

  • Who are TolerogenixX’s competitors?

    Maxion Therapeutics, SciRhom, and Quell Therapeutics are competitors of TolerogenixX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process